Literature DB >> 9473757

Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection.

A Tchirkov1, J Kanold, M Giollant, P Halle-Haus, M Berger, C Rapatel, P Lutz, C Bergeron, D Plantaz, J P Vannier, J L Stephan, M Favrot, P Bordigoni, P Malet, G Briançon, F Deméocq.   

Abstract

BACKGROUND: Autologous peripheral blood stem cell (PBSCs) are frequently used to reconstitute hematopoiesis following administration of megatherapy in children with advanced stage IV neuroblastoma. Some centers prefer the use of autografts enriched for CD34+ progenitor cells because the positive selection procedure is believed to reduce indirectly tumor cell contamination. PROCEDURES: In this study, we monitored the efficiency of tumor cell purging following CD34 selection in PBSCs from seven patients with advanced neuroblastoma by using a highly sensitive reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, Amplification of tissues-specific mRNA transcript of tyrosine hydroxylase gene with nested primers enabled the detection of residual neuroblastoma cells with a sensitivity of one malignant-cell per 10(6) normals.
RESULTS: Using this method, contaminating tumor cells were detected in seven of nine leukapheresis products of the patients. After positive immunoselection of CD34+ cells on Ceprate column, only one of nine enriched stem cell fraction still contained tumor cells detectable by RT-PCR. In six cases, PCR positive PBSCs became PCR negative after selection.
CONCLUSIONS: We conclude that tumor cell contamination may be frequently detected in PBSC harvests of stage IV neuroblastoma patients by sensitive molecular analysis. The load of contaminating malignant cells might be reduced following CD34 selection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9473757     DOI: 10.1002/(sici)1096-911x(199804)30:4<228::aid-mpo4>3.0.co;2-i

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  4 in total

Review 1.  Micrometastases in neuroblastoma: are they clinically important?

Authors:  S A Burchill
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

Review 2.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

3.  Label-free neuroblastoma cell separation from hematopoietic progenitor cell products using acoustophoresis - towards cell processing of complex biological samples.

Authors:  Franziska Olm; Anke Urbansky; Josefina H Dykes; Thomas Laurell; Stefan Scheding
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

4.  Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs.

Authors:  Natarajan Aravindan; Dinesh Babu Somasundaram; Terence S Herman; Sheeja Aravindan
Journal:  Cell Biol Toxicol       Date:  2020-09-26       Impact factor: 6.819

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.